远程筛查无症状心房颤动:AMALFI随机临床试验
AMALFI是一项平行组、非盲、远程随机临床试验,从英国27家初级保健机构纳入65岁以上、CHA2DS2VASc评分男性≥3分或女性≥4分且无房颤或房扑史者5040例,随机分为邮寄14天贴片式动态心电图筛查组(n=2520)或常规护理组(n=2520)。2.5年时干预组房颤记录比例6.8% vs 对照组5.4%(比例比1.26,95%CI 1.02-1.57;P=0.03),口服抗凝暴露平均增加0.50个月(95%CI 0.24-0.75;P<0.001),卒中发生率两组无显著差异(率比1.08,95%CI 0.76-1.53)。
要点
- 邮寄贴片式动态心电图筛查使2.5年房颤诊断比例从5.4%升至6.8%(比例比1.26,95%CI 1.02-1.57)。
- 干预组口服抗凝暴露平均增加0.50个月(95%CI 0.24-0.75;P<0.001)。
- 卒中发生率干预组2.7% vs 对照组2.5%(率比1.08,95%CI 0.76-1.53),无显著差异。
核心结论
- 在远程随机临床试验中,对卒中中高危老年患者采用邮寄心电图贴片进行房颤筛查,使2.5年时房颤诊断出现适度长期增加。
研究设计与样本
- 平行组、非盲、远程随机临床试验,2019年5月2日至2022年2月28日从英国27家初级保健机构招募。
- 纳入65岁及以上、CHA2DS2VASc评分男性≥3分或女性≥4分、无房颤或房扑史者,通过自动化电子健康记录搜索识别。
- 共邀请22044人,随机化5040人(22.9%);干预组n=2520接受邮寄心电图贴片监测并寄回,对照组n=2520接受常规护理。
- 主要分析为意向性治疗,主要结局为随机化后2.5年内初级保健记录中房颤的比例;末次随访2024年8月29日,统计分析于2025年5月至7月进行。
主要发现
- 参与者平均(SD)年龄78(6)岁,47%为女性,CHA2DS2VASc评分中位数(IQR)为4(3-5)。
- 2126例参与者(84.4%)佩戴并寄回贴片;贴片检出房颤89例(4.2%),其中55%房颤负荷低于10%。
- 随机化后2.5年,干预组172例(6.8%) vs 对照组136例(5.4%)有房颤记录(比例比1.26,95%CI 1.02-1.57;P=0.03),预设亚组结果一致。
- 2.5年时平均口服抗凝暴露干预组1.63个月(95%CI 1.50-1.76) vs 对照组1.14个月(95%CI 1.01-1.26),差值0.50个月(95%CI 0.24-0.75;P<0.001)。
- 卒中发生于干预组69例(2.7%) vs 对照组64例(2.5%),率比1.08(95%CI 0.76-1.53)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Screening for atrial fibrillation (AF) might reduce stroke if it increases long-term AF detection and anticoagulation use compared with usual care. OBJECTIVE: To investigate the long-term efficacy of AF screening in older individuals at moderate to high risk of stroke using 14-day, patch-based continuous ambulatory electrocardiogram (ECG) monitoring. DESIGN, SETTING, AND PARTICIPANTS: A parallel-group, unblinded, remote randomized clinical trial recruiting from 27 UK primary care practices from May 2, 2019, to February 28, 2022. All eligible individuals 65 years or older with a CHA2DS2VASc score of 3 or higher (men) or 4 or higher (women) with no previous AF or atrial flutter were identified via automated electronic health record searches. Last follow-up was on August 29, 2024, and statistical analysis was conducted from May to July 2025. INTERVENTION: Participants were randomized to receive and return an ECG patch monitor by postal mail (intervention, n = 2520) or usual care (control, n = 2520). MAIN OUTCOMES AND MEASURES: Intention-to-treat analysis of the proportion of participants with AF recorded in primary care records within 2.5 years postrandomization. Exploratory outcomes included exposure to oral anticoagulation and stroke. RESULTS: Of the 22 044 individuals invited, 5040 (22.9%) were randomized. The participants' mean (SD) age was 78 (6) years, 47% were female, and the median (IQR) CHA2DS2VASc score was 4 (3-5). A total of 2126 participants (84.4%) wore and returned the patch. AF was detected by patch in 89 participants (4.2%), 55% of whom had an AF burden less than 10%. After 2.5 years, a postrandomization record of AF was present in 172 individuals (6.8%) in the intervention group vs 136 (5.4%) in the control group (ratio of proportions, 1.26 [95% CI, 1.02-1.57]; P = .03), with consistent results in prespecified subgroups. Mean exposure to oral anticoagulation by 2.5 years was 1.63 months (95% CI, 1.50-1.76) in the intervention group and 1.14 months (95% CI, 1.01-1.26) in the control group (difference, 0.50 months [95% CI, 0.24-0.75]; P < .001). Stroke occurred in 69 participants (2.7%) in the intervention group and 64 (2.5%) in the control group (rate ratio, 1.08 [95% CI, 0.76-1.53]). CONCLUSIONS AND RELEVANCE: In this remote randomized clinical trial, mail-based AF screening with an ECG patch in older patients at moderate to high risk of stroke led to a modest long-term increase in AF diagnosis at 2.5 years. TRIAL REGISTRATION: ISRCTN Identifier: 15544176.
引用
- Wijesurendra R, Pessoa-Amorim G, Buck G, et al. Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial. JAMA. 2025. PMID: 40878848. doi:10.1001/jama.2025.15440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。